In our present study, we show that melanoma cells tolerated the replacement of endogenous XPD with XPD-R722W, demonstrating that the TTD mutation did not interfere with vital tumor cell functions at least under in vitro conditions. This evidence concerns the gene ERCC2 and melanoma.